OR4Q3

Across TCGA pan-cancer cohorts, OR4Q3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR4Q3 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher OR4Q3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR4Q3 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

ESCA, LUAD, and LUSC are the cancer types where OR4Q3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	24	view →
LUAD	DFS	Median	II,III,IV	0.667	0.438	<.001	7	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
SCLC	DFS	Median	All	0.295	0.837	.018	3	view →
BLCA	DFS	Median	III,IV	0.233	0.550	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR4Q3–ESCA (OS)

Open the ESCA breakdown →